Gradipore Strengthens Worldwide Leadership With New Board Member Additions
Pivotal Appointments in Key Regions Enhance Global Presence
SYDNEY (September 25, 2001) - Gradipore, a global biotechnology company (ASX Code: GDP) appoints two highly recognized experts in healthcare and the globalization of technology-based companies to the company's non-executive U.S. and Australian boards of directors. The additions of Dr. Arthur Hull Hayes, appointed to the company's U.S. board on October 1, 2001 and Leslie Webb, appointed to the Gradipore Australian board on September 25th, 2001, strengthen an already elite representation of science and business leaders as well as the company's worldwide presence by providing expert leadership in key locations.
Gradipore Inc. is the U.S. subsidiary of Gradipore Limited, located in Sydney, Australia. Both the parent company and the subsidiary maintain separate boards of directors.
"Gradipore's strategy of global growth is enhanced exponentially by the appointments of Dr. Hayes and Mr. Webb," said John Manusu, executive chairman for Gradipore. "Together, they offer a strong track record of success in managing science, medicine and business innovation on an international level. This experience will be invaluable in leading Gradipore toward our goal of becoming the global technology leader by setting new standards in biological separations."
Dr. Hayes is a former Commissioner of Food and Drugs at the United States Food and Drug Administration (FDA), and a former Assistant Surgeon General. He was also Provost and Dean, Professor of Medicine, Pharmacology and Family & Community Medicine, and Director of the Institute of Human Values in Medical Ethics at The New York Medical College.
Dr. Hayes is a past President, CEO and member of the board of directors of EM Pharmaceuticals, Inc., a North American subsidiary of E. Merck, Darmstadt, Germany.He is the founder of MediScience Associates - the regulatory/medical consulting division of Nelson Communications, Inc. - where he continues to serve as President; as well as Vice Chairman, Medical Director and member of the board of directors of Nelson Communications, Inc. Dr. Hayes also holds faculty positions at Pennsylvania State Medical College.
The recipient of numerous scientific and public service awards and honors, Dr. Hayes is a Charter Diplomate of the American Board of Clinical Pharmacology and a Fellow of the American Colleges of Physicians, Cardiology, Chest Physicians, and Clinical Pharmacology and the American Academy of Pharmaceutical Physicians, the New York Academy of Medicine and the Royal College of Medicine. He holds three honorary degrees.
Dr. Hayes serves on a number of academic, commercial and foundation boards of directors, advisory committees and editorial boards, has held various visiting professorships and Lectureships and has served as a consultant on scientific, pharmaceutical and regulatory issues to several national governments. He has engaged in the private practice of medicine, and has published over 100 scientific and public policy articles and book chapters, delivered numerous professional lectures and has testified at US Congressional hearings as well as at state legislative hearings.
An expert in the globalization of technology-based companies, Mr. Webb serves as a Barrister of the Supreme Court of New South Wales, Barrister and Solicitor of the Supreme Court of Victoria and Barrister and Solicitor of the High Court of Australia. He has consulted extensively with both publicly listed and unlisted companies in the biotechnology and information technology industries on corporate and financial planning, intellectual property, corporate governance and strategic planning issues.
Mr. Webb has represented Australian Companies in Asia, Europe and the U.S. and has been involved in planning and advice in relation to the Public listing of companies on global exchanges, including the Australian Stock Exchange (ASX) and the NASDAQ. As a result of his extensive global involvement on behalf of Australian companies, he has amassed a valuable network of global contacts particularly in the U.S., Europe and in Asia.
A graduate of Melbourne University, Mr. Webb also maintained a private law practice, Slade & Webb.
About Gradipore
Gradipore (ASX Code: GDP) is a global biotechnology company that researches, develops, manufactures and markets hematological and separation technologies principally to provide increased efficiency for research and development for the life science market throughout the world. The company's mission is to become the global technology leader by setting new standards of performance in biological separations. Gradipore's core separations technology platform, Gradiflow(TM), is a unique membrane-based process for large-scale biological separations and has a wide range of applications in research, scientific and commercial environments including blood purification and biological drug manufacturing.
Gradiflow is used in conjunction with the company's line of electrophoresis gels, marketed as iGels(TM), an essential scientific laboratory measuring tool used in most biochemical separations. iGels, offer several competitive advantages including high resolution and reproducibility. Because they are manufactured in a patented plastic cassette instead of traditional glass, iGels are safer, portable, and less expensive than alternative products.
For more information, visit Gradipore's web site at http://www.gradipore.com.
For further information, please contact:
Gradipore Limited
Kate Leeder
61 2 8977 9093
mailto:kleeder@gradipore.com